Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | NOS2 | P35228 | 2/20 | 0.41 |
| ▸ | HTR7 | P34969 | 4/20 | 0.36 |
| ▸ | HTR6 | P50406 | 4/20 | 0.36 |
| ▸ | DRD2 | P14416 | 3/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.35 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.31 |
| ▸ | CTSA | P10619 | 1/20 | 0.31 |
| ▸ | FERMT2 | Q96AC1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL6495070 | 0.93 | CYP2D6 (0.41) | CYP2D6SLC6A2SLC6A4NOS2HTR7 | |
| SCHEMBL6495511 | 0.75 | CYP1A2 (0.33) | CYP2D6CTSA | |
| SCHEMBL6496091 | 0.75 | CYP2D6 (0.41) | CYP2D6SLC6A2SLC6A4NOS2HTR7 | |
| Hydrochloric Acid SCHEMBL6502132 | 0.74 | CYP2D6 (0.40) | CYP2D6SLC6A2SLC6A4NOS2HTR7 | |
| SCHEMBL6490842 | 0.72 | NOS2 (0.47) | CYP2D6SLC6A2SLC6A4NOS2HTR7 | |
| Oxalic Acid SCHEMBL6497943 | 0.68 | NOS2 (0.47) | CYP2D6SLC6A2SLC6A4NOS2CTSA | |
| SCHEMBL6495073 | 0.67 | CTSA (0.35) | CTSA | |
| SCHEMBL6490849 | 0.66 | NOS2 (0.39) | NOS2HTR2ACTSA | |
| SCHEMBL5651711 | 0.64 | NOS2 (0.54) | CYP2D6SLC6A2SLC6A4NOS2HTR7 | |
| SCHEMBL6501546 | 0.64 | NOS2 (0.61) | CYP2D6SLC6A2SLC6A4NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6953797-B2 | Use of phenylheteroalkylamine derivatives | ASTRAZENECA AB (SE) | 2005-10-11 | — | — | US | claimed |
| EP-1263718-B1 | NOVEL USE OF PHENYLHETEROALKYLAMINE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-04-28 | — | — | EP | claimed |
| US-20030073685-A1 | Novel use of phenylheteroalkylamine derivatives | ASTRAZENECA AB (SE) | 2003-04-17 | — | — | US | claimed |
| EP-1263718-A1 | NOVEL USE OF PHENYLHETEROALKYLAMINE DERIVATIVES | AstraZeneca AB (SE) | 2002-12-11 | — | — | EP | claimed |
| WO-2001062721-A1 | NOVEL USE OF PHENYLHETEROALKYLAMINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-08-30 | — | — | WO | claimed |
| US-6953797-B2 | Use of phenylheteroalkylamine derivatives | ASTRAZENECA AB (SE) | 2005-10-11 | — | — | US | disclosed |
| EP-1263718-B1 | NOVEL USE OF PHENYLHETEROALKYLAMINE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-04-28 | — | — | EP | disclosed |
| US-20030073685-A1 | Novel use of phenylheteroalkylamine derivatives | ASTRAZENECA AB (SE) | 2003-04-17 | — | — | US | disclosed |
| EP-1263718-A1 | NOVEL USE OF PHENYLHETEROALKYLAMINE DERIVATIVES | AstraZeneca AB (SE) | 2002-12-11 | — | — | EP | disclosed |
| WO-2001062721-A1 | NOVEL USE OF PHENYLHETEROALKYLAMINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073685-A1 | Novel use of phenylheteroalkylamine derivatives | CYP1A1, CYP1A2, CYP2E1 | CYP2D6 38/4885SLC6A2 1769/4885SLC6A4 1977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.